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1. Abstract  
Diabetes induces changes in neurotransmitter release in central nervous system, which 
depend on the type of neurotransmitter and region studied. In this study, we evaluated 
the effect of diabetes (two and eight weeks duration) on basal and evoked release of 
[14C]glutamate and [3H]GABA in hippocampal and retinal synaptosomes. We also 
analyzed the effect of diabetes on the protein content of vesicular glutamate and GABA 
transporters, VGluT-1, VGluT-2 and VGAT, and on the α1A subunit of P/Q type calcium 
channels, which are abundant in nerve terminals. 
The protein content of vesicular glutamate and GABA transporters, and of the α1A 
subunit, was differently affected by diabetes in hippocampal and retinal synaptosomes. 
The changes were more pronounced in the retina than in hippocampus. VGluT-1 and 
VGluT-2 content was not affected in hippocampus. Moreover, changes occurred early, 
at two weeks of diabetes, but after eight weeks almost no changes were detected, with 
the exception of VGAT in the retina. Regarding neurotransmitter release, no major 
changes were detected. After two weeks of diabetes, neurotransmitter release was 
similar to controls. After eight weeks of diabetes, the basal release of glutamate slightly 
increased in hippocampus and the evoked GABA release decreased in retina.  
In conclusion, diabetes induces early transient changes in the content of glutamate 
and/or GABA vesicular transporters, and on calcium channels subunit, in retinal or 
hippocampal synaptosomes, but only minor changes in the release of glutamate or 
GABA. These results point to the importance of diabetes-induced changes in neural 
tissues at the presynaptic level, which may underlie alterations in synaptic 
transmission, particularly if they become permanent during the later stages of the 
disease.  
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2. Introduction 
Diabetes mellitus is a metabolic disease resulting from impairment in insulin secretion 
and/or insulin resistance leading to hyperglycemia. Diabetes is associated with several 
diseases, such as diabetic encephalopathy and retinopathy (ADA, 2010), which are 
characterized by functional and structural alterations in brain and retina, respectively. 
Several studies have demonstrated that diabetes impairs synaptic structure and 
function in hippocampus at presynaptic (Grillo et al., 2005; Gaspar et al., 2010) and 
postsynaptic levels (Biessels et al., 1996; Kamal et al., 1999), which can somehow 
underlie the development of cognitive impairments. In diabetic animals, changes in the 
content of exocytotic proteins and receptors involved in neuromodulation in 
hippocampal nerve terminals (Duarte et al., 2006; Duarte et al., 2007; Duarte et al., 
2009; Gaspar et al., 2010), and a depletion of synaptic vesicles in hippocampal mossy 
fiber terminals (Magarinos and McEwen, 2000), have been detected. At the 
postsynaptic component, impairments in synaptic plasticity (Biessels et al., 1996; Artola 
et al., 2005) and in NMDA receptor subunit composition (Trudeau et al., 2004) were 
also observed. Furthermore, Chabot et al. (1997) reported a deficit in calcium-
dependent processes modulating postsynaptic AMPA receptors during synaptic 
potentiation. Diabetes also triggers changes in neurotransmitter release in various 
brain regions, which depend on neurotransmitter and brain region studied (Guyot et al., 
2001; Morris and Pavia, 2004; Miyata et al., 2007; Satoh and Takahashi, 2008). For 
instance, diabetes decreases the basal release levels of serotonin and dopamine in 
hippocampus (Yamato et al., 2004) and of glutamate in the dentate gyrus, but basal γ-
aminobutyric acid (GABA) release is not affected (Reisi et al., 2009). 
In the retina, the presynaptic component is also affected under diabetic conditions, 
since a decrease in the levels of several exocytotic proteins in retinal nerve terminals 
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was recently reported (Vanguilder et al., 2008; Gaspar et al., 2010). In the retina of 
diabetic animals and in retinal neural cell cultures exposed to elevated glucose, we 
found an increase in the evoked release of [3H]D-aspartate (marker of the glutamate 
transmitter pool) (Santiago et al., 2006a) and ATP (Costa et al., 2009). Moreover, 
elevated levels of GABA and glutamate were detected in the vitreous of patients with 
proliferative diabetic retinopathy (Ambati et al., 1997). We also reported that diabetes 
changes the content of ionotropic glutamate receptor subunits in the retina, which may 
account to retinal dysfunction (Santiago et al., 2009). In addition, it has been suggested 
that changes in GABA signalling may underlie the alterations in electroretinogram 
(ERG) responses in streptozotocin (STZ)-induced diabetic rats (Ramsey et al., 2006) 
and diabetic patients (Ambati et al., 1997). Diabetes modulates the properties of 
GABAC receptors in retinal bipolar cells, probably through alterations in the gene 
expression of GABA receptor subunits, which might therefore underlie changes in ERG 
of diabetic patients (Ramsey et al., 2007). In the retina of diabetic animals, changes in 
the content and localization of GABA are evident, with both amacrine and Müller cells 
accumulating high concentration of GABA (Ishikawa et al., 1996; Takeo-Goto et al., 
2002). Moreover, diabetes leads to a generalized attenuation in the content of free 
amino acids in the retina and to a decrease in the uptake of aspartate, while GABA 
uptake is enhanced (Vilchis and Salceda, 1996). However, by nuclear magnetic 
resonance spectroscopy, we recently showed that the levels of the majority of the 
intermediate metabolites and amino acids present in retina is not affected by diabetes 
(Santiago et al., 2010). 
Importantly, the synaptic level of GABA and glutamate is determined by two important 
factors: the integrity of the release and re-uptake systems. In nerve terminals, specific 
vesicular transporters (VGluT1-3 for glutamate, and VGAT for GABA) allow the 
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incorporation of neurotransmitters into synaptic vesicles. These transporters have an 
essential role in transmitter recycling and homeostasis in the CNS, and several studies 
evidence their role in neurological disorders (Vemuganti, 2005; Benarroch, 2010).  
Other key elements involved in neurotransmitter release are voltage-dependent 
calcium channels which mediate the entry of Ca2+ ions into nerve terminals. Calcium 
channels are multisubunit complexes composed of α1, β, α2/δ, and γ subunits. The 
channel activity is directed by the pore-forming α1 subunit, whereas the others act as 
auxiliary subunits regulating this activity. The α1A subunit is predominantly expressed in 
neuronal tissues (Evans and Zamponi, 2006). N- and P/Q-type Ca2+ channels are 
important in the presynaptic control of amino acid release in the hippocampus (Meir et 
al., 1999). These channels have an important contribution for endogenous glutamate 
release from hippocampal synaptosomes, being the contribution of P/Q-type channels 
for the release of glutamate more relevant than the contribution of N-type (Ambrósio et 
al., 1997).  
Thus, our previous observations showing that diabetes changes the protein content of 
several exocytotic proteins in rat hippocampal and retinal nerve terminals (Gaspar et 
al., 2010) has prompted us to detect further alterations that occur at the presynaptic 
level and mapping the effect of diabetes on basal and evoked glutamate and GABA 
release in hippocampus and retina. In this study, we focused on retina and 
hippocampus not only because they are prone to diabetic neuropathy, but also based 
on our previous results, where we observed presynaptic changes and where one would 
expect impairment at the synaptic level. Moreover, since the release of glutamate and 
GABA depend on the transport of the amino acids into synaptic vesicles, we also 
evaluated the content of VGluT-1, VGluT-2 and VGAT, searching for possible 
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impairments in these proteins under diabetic conditions, and aiming to correlate 
possible changes with alterations in neurotransmitter release.  
 
2. Results 
2.1 Animal weight and glycemia 
Before diabetes induction, the body weight of animals assigned for control and diabetic 
groups was similar (289.9 ± 5.1 g for control and 284.6 ± 7.8 g for diabetic animals). 
The glucose levels were also similar in both groups (91.5 ± 2.4 mg/dL for controls and 
86.0 ± 3.5 mg/dL for diabetic animals). Average weight and blood glucose levels for 
both diabetic and aged-matched control rats at the time of death are given in Table 1. A 
marked impairment in weight gain occurred in diabetic rats comparing with age-
matched controls in both time points analyzed. Diabetic animals also presented 
significantly higher blood glucose levels comparing to age-matched controls (Table 1). 
 
2.2 Diabetes changes the protein content of vesicular glutamate transporters in 
retinal synaptosomes 
The protein levels of vesicular glutamate transporters were evaluated by 
immunoblotting in synaptosomes and total extracts of hippocampus and retina from 
both diabetic and age-matched control animals. In hippocampal synaptosomes, VGluT-
1 and VGluT-2 content was not affected after two and eight weeks of diabetes (Figures 
1A and 1B, respectively). In retinal synaptosomes, the protein content of VGluT-1 and 
VGluT-2 significantly decreased after two weeks of diabetes (reduction to 69.5 ± 8.8% 
and 77.5 ± 8.2%, respectively, compared to age-matched controls; Figures 2A and 2B). 
However, after eight weeks of diabetes no significant changes were observed in retinal 
synaptosomes. In total extracts from hippocampus (Figures 1C and 1D) and retina 
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(Figures 2C and 2D) no significant differences were detected in the protein content of 
both vesicular transporters between diabetic and age-matched control animals. 
 
2.3 Diabetes changes the protein content of vesicular GABA transporter in 
hippocampal and retinal synaptosomes 
The protein content of VGAT significantly decreased after two weeks of diabetes, both 
in hippocampal and retinal synaptosomes (reduction to 75.8 ± 6.4% and 44.7 ± 3.3%, 
respectively; Figures 3A and 3B,). However, eight weeks after the onset of diabetes, 
the protein levels of VGAT in hippocampal synaptosomes were similar to those found 
in age-matched controls. Surprisingly, the protein levels of VGAT significantly 
increased in retinal synaptosomes (143.2 ± 3.9%; Figure 3B). In total extracts from 
hippocampus and retina, no significant differences were observed in the protein levels 
of VGAT between diabetic animals and age-matched controls (Figures 3C and 3D, 
respectively). 
 
2.4 The protein content of the subunit α1A of P/Q calcium channels decreased 
after two weeks of diabetes in hippocampal and retinal synaptosomes 
The protein content of α1A subunit of P/Q type calcium channels significantly decreased 
in hippocampal and retinal synaptosomes (reduction to 77.6 ± 6.4% and 55.2 ± 3.0% of 
age-matched controls, respectively) after two weeks of diabetes (Figures 4A and 4B). 
Conversely, eight weeks after the onset of diabetes, the protein levels of α1A subunit in 
synaptosomes from both tissues were similar to those found in controls. In total 
extracts from hippocampus and retina, no significant changes were observed in the 
protein levels of this subunit (Figures 4C and 4D). 
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2.5 The basal release of [14C]glutamate increased in hippocampal synaptosomes 
after eight weeks of diabetes, but [3H]GABA release was not affected by diabetes 
The effect of diabetes on [14C]glutamate and [3H]GABA release from hippocampal 
synaptosomes was also evaluated. After two weeks of diabetes, no differences were 
found in the basal release of [14C]glutamate between diabetic and age-matched control 
animals (Figure 5A). However, after eight weeks, a small but significant increase in the 
basal release of [14C]glutamate was found in diabetic animals (2.42 ± 0.02 FR% for 
control and 2.74 ± 0.02 FR% for diabetic animals; Figure 5B). The amplitude of the 
repeated KCl-evoked release of [14C]glutamate (S1 and S2) in synaptosomes isolated 
from two and eight weeks diabetic and control animals was not significantly different 
(Figures 5C and 5D). The S2/S1 ratio was also determined, but no differences were 
found between diabetic and control animals for both time points (Figure 5E). 
Regarding [3H]GABA release, no changes were observed in diabetic animals, either in 
basal or evoked release, as well as for S2/S1 ratio, at two and eight weeks of diabetes 
(Figure 6).  
 
2.6 [3H]GABA release decreased after eight weeks of diabetes in retinal 
synaptosomes 
In retinal synaptosomes, we only measured the release of [3H]GABA because the 
radioactive levels obtained for [14C]glutamate release experiments were too low. The 
basal release of [3H]GABA before the first stimulus was similar in both control and 
diabetic animals after two and eight weeks of diabetes (Figures 7A and 7B). After two 
weeks of diabetes, the KCl-evoked [3H]GABA release (S1 and S2) was similar to the 
one observed in age-matched control animals (Figure 7A and 7C). However, after eight 
weeks of diabetes there was a significant decrease in [3H]GABA release after the 
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second stimulus (4.68 ± 0.26 FR% for control and 3.96 ± 0.31 FR% for diabetic 
animals, respectively; Figures 7B and 7D). Consequently, the S2/S1 ratio at eight 
weeks of diabetes, but not at two weeks of diabetes, was significantly decreased 
compared to control (Figure 7E). 
 
3. Discussion  
In the present study, we demonstrated that diabetes induces transient changes in the 
protein content of vesicular glutamate and GABA transporters and also in the α1A 
subunit of P/Q type calcium channels. Hippocampal and retinal nerve terminals, were 
differently affect by diabetes, however no changes were observed in total extracts. 
Moreover, our results show that after eight weeks of diabetes there is a slight increase 
in the basal release of glutamate in hippocampal synaptosomes and a slight decrease 
in the evoked release of GABA in retinal synaptosomes. A fine balance between GABA 
and glutamate is essential for a proper brain and retinal function and any imbalance 
may lead to physiological alterations. Although these changes, particularly those 
related with neurotransmitter release, are only slight changes, this study shows that 
diabetes can affect the pre-synaptic compartment in neuronal issues, and also that the 
balance between glutamate and GABA might be affected early under diabetic 
conditions in both tissues. 
Alterations in memory and cognitive deficits (Biessels et al., 1996), and contrast 
sensitivity and color perception (Roy et al., 1986; Daley et al., 1987), induced by 
diabetes, might be due, at least in part, to changes in neurotransmission, at pre- and/or 
post-synaptic level. Recently, we demonstrated that diabetes induces changes in the 
content of several synaptic proteins involved in exocytosis in both hippocampal and 
retinal synaptosomes (Gaspar et al., 2010), suggesting that diabetes might impair 
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neurotransmitter release early in the course of the disease. However, there are only 
three studies exploring the impact of diabetes on transmitter release in hippocampus. 
One shows that the basal release of monoamines is impaired in both STZ-injected and 
spontaneously diabetic rats (WBN/Kob rats) (Yamato et al., 2004). (Ramakrishnan et 
al., 2005)) reported an increase in the levels of dopamine. Other work shows that the 
basal release of glutamate in dentate gyrus is decreased after twelve weeks of 
diabetes (Reisi et al., 2009). Similarly, in the retina, there are a few studies where the 
effect of diabetes or hyperglycemic conditions on neurotransmitter release was 
analyzed. In the retina of diabetic animals and in high glucose-treated retinal neural cell 
cultures, we showed that the release of [3H]D-aspartate is increased (Santiago et al., 
2006a). Similarly, we found that the release of ATP in retinal cell cultures exposed to 
high glucose is also increased (Costa et al., 2009). 
VGluT-1 and -2 are specific markers for glutamatergic neurons, and changes in their 
content may underlie changes in glutamatergic transmission (Benarroch, 2010; Phillips 
et al., 2010). The content of VGluT-1 and -2 was differently affected by diabetes in both 
tissues. No changes in VGluT-1 and -2 were detected in hippocampal synaptosomes, 
but a significant decrease in the content of both transporters was observed in retinal 
synaptosomes after two weeks of diabetes. The content of VGAT decreased in both 
hippocampal and retinal synaptosomes after two weeks of diabetes. These 
observations suggest that the retina appears to be more affected than hippocampus by 
diabetes, concerning the transport of neurotransmitters, namely glutamate and GABA, 
into the vesicles. The decrease in VGAT and VGluT-1 and -2 content in synaptosomes 
could lead to a slower packaging of GABA and glutamate which can contribute to 
changes in synaptic transmission. However, our results suggest that although the 
protein content of VGAT and P/Q proteins is affected at two weeks, the loading 
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capacity of vesicular transporters appears not to be changed by diabetes, since the 
uptake of [3H]GABA into synaptosomes was not affected. However, the decrease in the 
levels of the vesicular transporters was transient, at least in the early stages of 
diabetes, suggesting that after the initial stress conditions induced by diabetes both 
tissues are somehow able to react against diabetes-induced stress. In a previous work, 
we found that the content of synaptic proteins in retinal synaptosomes is affected 
mainly after two weeks of diabetes, recovering to control levels for longer periods 
(Gaspar et al., 2010), suggesting that changes can be plastic and reversible, and 
neural tissues are able to react against stress conditions, at least temporarily. 
The P/Q type voltage-gated calcium channels are abundant in nerve terminals and play 
a predominant role in neurotransmitter release at central synapses (Ambrósio et al., 
1997). P/Q type calcium channels co-localize densely with syntaxin-1 at the 
presynaptic nerve terminals (Westenbroek et al., 1995) and can be isolated as a 
complex with SNARE proteins (Bennett et al., 1992; Leveque et al., 1994). As for 
vesicular transporters, hippocampus and retina recovered the levels of α1A subunit after 
eight weeks of diabetes, supporting the fact that both tissues are able to recover from 
changes occurring in synaptic proteins induced by diabetes, at least temporarily. 
Impaired Ca2+ regulation may result in synaptic dysfunction, impaired plasticity and 
neuronal degeneration (Mattson, 2007). Elevated glucose impairs calcium homeostasis 
in retinal neural cells, which may have implications for the mechanisms of vision loss in 
diabetic retinopathy (Santiago et al., 2006b). The observed decrease in the levels of 
α1A subunit in diabetic animals might be considered a protective strategy against Ca
2+ 
overload.  
A few studies have demonstrated that diabetes induces changes in neurotransmitter 
release. In this study, after two weeks of diabetes, no differences were found in 
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neurotransmitter release in hippocampus and retina. However, after eight weeks of 
diabetes, the evoked release of GABA is slightly, but significantly, decreased in retinal 
synaptosomes, and the basal release of glutamate is slightly, but also significantly, 
increased in hippocampal synaptosomes. We are aware of only three studies reporting 
changes in transmitter release in the diabetic hippocampus: while (Yamato et al., 2004)  
found a decrease in the basal levels of serotonin and dopamine, (Ramakrishnan et al., 
2005) reported an increase in the levels of dopamine. The apparent contradiction may 
be explained by the different time-points of the disease investigated. Altogether, a 
growing body of evidence suggests that diabetes impairs hippocampal 
neurotransmission. 
The accumulation of glutamate in the synaptic cleft can lead to excitotoxic neuronal 
damage due to excessive activation of glutamate receptors (Dong et al., 2009). The 
small increase in the basal release of glutamate can be responsible for glutamate 
accumulation in the synaptic cleft. If this small increase in basal glutamate release 
occurs during long periods, it may eventually contribute to neurotoxicity. In 
experimental models, it has been shown that diabetes does not induce 
neurodegeneration in the brain at early time points (eight weeks) of diabetes (Grillo et 
al., 2005). However, after longer periods of diabetes (eight months), neuronal 
apoptosis can occur (Li et al., 2002). In fact, small changes for longer periods of time 
might progressively conduct to neuronal cell dysfunction and death, as observed in the 
hippocampus of diabetic animals (Li et al., 2002; Jafari Anarkooli et al., 2008), which in 
turn might be associated with cognitive impairments. Reisi and colleagues (2009) 
recently reported that the basal glutamate release decreases in the dentate gyrus of 
STZ-induced diabetic animals, while we found an increase in whole hippocampus. This 
discrepancy may be due to the experimental approaches used. While we measured the 
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release of glutamate and GABA in hippocampal synaptosomes in a superfusion 
system, Reisi and colleagues (2009) measured the release using a microdialysis 
system and only in dentate gyrus. However, concerning GABA release, no differences 
were found, similarly to what was observed by Reisi and colleagues. Notwithstanding, 
Li et al. (2000) have shown that hyperglycemia exacerbates the ischemia-triggered 
increase of extracellular glutamate concentration in the hippocampus and cortex. This 
is important because the removal of the neurotransmitters by the transporter systems is 
highly energy dependent. We recently found that the cerebral glucose uptake and 
metabolism in STZ-induced diabetic rats is also compromised (unpublished 
observation). Thus, it is likely that highly energy-dependent processes such as the 
reuptake of neurotransmitters may also be affected in type-1 diabetes. Some studies 
suggest that the impairments in glutamatergic neurotransmission, at postsynaptic level, 
involving the reorganization of post-synaptic receptors underlie the functional changes 
in synaptic plasticity that occur in the hippocampus of diabetic animals (Di Luca et al., 
1999; Gardoni et al., 2002). Our findings suggest that diabetes can elicit alterations in 
excitatory neurotransmission, at presynaptic level, but additional experiments are 
needed to establish a clear correlation with changes in glutamatergic transmission and 
cell dysfunction or death in hippocampal neurons. 
In the retina, we found no changes in the release of GABA at two weeks of diabetes. 
However, at eight weeks of diabetes we found a small, but significant, impairment in 
the evoked release of GABA, during the second stimulus. Previously, we demonstrated 
that the evoked release of [3H]D-aspartate from the retina increases at four weeks of 
diabetes, increasing also in retinal neural cultures exposed to high glucose (Santiago et 
al., 2006a). These observations, namely the decrease in the evoked [3H]GABA release 
and the increase in the evoked release of [3H]D-aspartate (marker of glutamate 
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transmitter pool) in the diabetic rat retinas suggests that diabetes can lead to the 
impairment of neurotransmission. Moreover, if these alterations in transmitter release 
persist for longer periods, they can somehow contribute to neuronal apoptosis detected 
in the diabetic retina (Barber et al., 1998; Park et al., 2003), which may be correlated to 
the hypothesis of glutamate-induced retinal neurodegeneration in diabetic retinopathy. 
Taken together, and according to our previous findings, these results further 
demonstrate that diabetes induces molecular alterations in both retinal and 
hippocampal nerve terminals. We report changes in the density of vesicular glutamate 
and GABA transporters and of α1A subunit of P/Q type calcium channels. Moreover, the 
alterations were more pronounced in the retina, and the majority of these changes 
were transient, which also suggests that retina and hippocampus are able to react 
against stress conditions, at least temporarily. The changes detected in nerve terminals 
at two weeks of diabetes did not correlate with changes in glutamate and GABA 
release. Changes in transmitter release, which were not very pronounced, were only 
detected at eight weeks of diabetes. If these changes persist or become more 
prominent, an imbalance between excitation and inhibition might take place in both 
tissues, which may lead to neuronal dysfunction, and ultimately to visual and memory 
impairments detected in diabetic animals and humans. 
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4. Experimental Procedures 
4.1 Materials 
Reagents were acquired from Sigma, St. Louis, MO, USA, with the exception of those 
described along the text. 
 
4.2 Animals 
Male Wistar rats (Charles River Laboratories, Barcelona, Spain), eight weeks-old, were 
randomly assigned to control or diabetic groups. All animals were handled according 
with the EU guidelines for the use of experimental animals (86/609/EEC). Diabetes was 
induced with a single intraperitoneal injection of streptozotocin (STZ; 65 mg/kg, freshly 
dissolved in 10 mM sodium citrate buffer, pH 4.5). Hyperglycemic status (blood glucose 
levels exceeding 250 mg/dL) was confirmed two days later with a glucometer (Elite, 
Bayer, Portugal). Before sacrifice under halothane anesthesia, rats were weighted, and 
blood samples were collected to measure glucose levels.  
 
4.3 Preparation of hippocampal synaptosomal extracts 
Percoll purified synaptosomes were isolated as previously described (Köfalvi et al., 
2007), with minor changes. The two hippocampi of each rat were dissected and 
homogenized in a sucrose-HEPES solution (0.32 M sucrose, 1 mM EDTA, 10 mM 
HEPES, 1 mg/mL BSA, pH 7.4). The homogenate was centrifuged at 3,000 x g for 10 
min at 4ºC. The supernatant was collected and centrifuged at 14,000 x g for 12 min at 
4ºC, and the resulting pellet was resuspended in 45% (v/v) Percoll solution prepared in 
Krebs–Henseleit Ringer (KHR) solution (in mM: 140 NaCl, 1 EDTA, 10 HEPES, 3 KCl, 
5 glucose, pH 7.4). After centrifugation at 16,100 x g for 2 min at 4ºC, the top layer was 
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removed (synaptosomal fraction). For release experiments, the synaptosomal fraction 
was collected and stored in a sealed container on ice until use. For synaptosomal 
extracts, pellet was resuspended in lysis buffer [RIPA: 150 mM NaCl, 50 mM Tris, 5 
mM EGTA, 1% Triton X-100, 0.5% sodium deoxycholate (DOC), 0.1% sodium dodecyl 
sulfate (SDS), supplemented with complete miniprotease inhibitor cocktail tablets 
(Roche, Basel, Switzerland) and 1 mM dithiothreitol (DTT)]. The samples were stored 
at -80ºC until use. 
 
4.4 Preparation of retinal synaptosomal extracts  
The two retinas of each diabetic and age-matched control rats were used for 
preparation of synaptosomes, as previously described (Vanguilder et al., 2008), with 
minor alterations. Immediately after animal sacrifice, both eyes were enucleated, and 
the two retinas were dissected and merged in 10 mL of ice-cold sucrose-HEPES 
solution. Retinas were washed three times combining gentle vortexing and buffer 
replacement to remove photoreceptor outer segments. Then, the retinas were 
homogenized in 4 mL of fresh sucrose buffer and then the homogenate was 
centrifuged at 200 x g for 10 min at 4ºC to pellet nuclear fraction. The supernatant was 
centrifuged at 800 x g for 12 min at 4ºC. The resulting supernatant was centrifuged at 
16,100 x g for 20 min at 4ºC to obtain the synaptosomal fraction used in release 
experiments. For synaptosomal extracts the pellet was rinsed in a detergent-based 
extraction buffer (20 mM Tris, 2 mM EDTA, 2 mM EGTA, 1% Triton X-100, 0.5% SDS, 
supplemented with complete miniprotease inhibitor cocktail tablets, pH 7.2), at 4ºC and 
stored at -80ºC until use. 
 
4.5 Preparation of hippocampal total extracts 
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After dissection, the two hippocampi were homogenized in lysis buffer (50 mM Tris-
HCl, pH 7.4, 0.5% Triton X-100, supplemented with complete mini protease inhibitor 
cocktail tablets and 1 mM DTT). The resulting homogenate was sonicated (4 pulses, 2 
seconds each) and then centrifuged at 16,100 x g for 10 min. All procedure was done 
at 4ºC. The supernatant was stored at -80ºC until use. 
 
4.6 Preparation of retinal total extracts 
The eyes of diabetic and age-matched control animals were enucleated and placed in 
cold phosphate-buffered saline [(PBS), in mM: 137 NaCl, 2.7 KCl, 10 Na2HPO4, 1.8 
KH2PO4, pH 7.4 at 4ºC]. The retinas were lysed in RIPA buffer supplemented with 
complete mini protease inhibitor cocktail tablets and 1 mM DTT, pH 7.2, at 4ºC. Then, 
the lysates were sonicated and centrifuged at 16,100 x g for 10 min at 4ºC. The 
supernatant was collected and stored at -80ºC until use. 
 
4.7 [3H]GABA and [14C]glutamate release assays for hippocampal synaptosomes 
Dual-label [3H]GABA / [14C]glutamate release experiments were performed as 
described by (Köfalvi et al., 2007), with some modifications. The synaptosomal pellet 
was ressuspended in 2 mL of Krebs solution [(in mM): 113 NaCl, 3 KCl, 1.2 KH2PO4, 
1.2 MgSO4, 2.5 CaCl2, 25 NaHCO3, 10 glucose, oxygenated with 95% O2 and 5% CO2, 
pH 7.4]. The radioalabeled compounds [1 μCi/mL [14C]glutamate and 2.3 μCi/mL 
[3H]GABA (Amersham Pharmacia Biotech, Piscataway, NJ, USA)] were added to the 
synaptosomes for 10 min at 37ºC. All solutions contained the GABA transaminase/ 
glutamate decarboxylase inhibitor, aminooxyacetic acid (100 µM). Aliquots (400 µL) of 
the preloaded synaptosomes were transferred to 1 mL of oxygenated Krebs solution 
and then to perfusion chambers, being trapped in Whatman GF/C filters and 
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superfused continuously at a rate of 0.75 mL/min until the end of the experiment. After 
a washout period (15 min), samples were collected (2 min perfusion) for liquid 
scintillation assay. The volume of sample (perfusate) that was collected in the vial for 
scintillation counting was 1.5 ml. All experimental procedures were performed at 37ºC. 
At the 4th and the 12th min of the sample collection period, release of transmitters was 
evoked with 20 mM KCl for 30 seconds each time (Köfalvi et al., 2007). 
 
4.8 [3H]GABA release assay for retinal synaptosomes 
Release experiments were performed as previously described by (Köfalvi et al., 2007), 
with some modifications. The synaptosomal pellet was resuspended in 1 mL of Krebs 
solution. The radioalabeled compound [4.2 μCi/mL [3H]GABA (Amersham Pharmacia 
Biotech, Piscataway, NJ, USA)] was added to the synaptosomes for 10 min at 37ºC. All 
solutions contained the GABA transaminase/ glutamate decarboxylase inhibitor, 
aminooxyacetic acid (100 mM). Aliquots (200 µL) of the preloaded synaptosomes were 
transferred to 1 mL of oxygenated Krebs solution and then to perfusion chambers, 
being trapped in Whatman GF/C filters and superfused continuously at a rate of 0.75 
mL/min until the end of the experiment. After a washout period (15 min), samples (2 
min perfusion) were collected for liquid scintillation assay. The volume of sample 
(perfusate) that was collected in the vial for scintillation counting was 1.5 ml. All 
experimental procedures were performed at 37ºC. At the 4th and the 12th min of the 
sample collection period, release of transmitters was evoked with with 30 mM KCl for 1 
min each time. In these release experiments, a 30 mM KCl stimulus was chosen 
because the evoked response triggered with 20 mM KCl in retinal synaptosomes was 
weak. 
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4.9 Western blot analysis 
The protein concentration of each sample was determined by the BCA protein assay 
(Pierce Biotechnology, Rockford, IL, USA). The samples were denaturated by adding 
6x concentrated sample buffer (0.5 M Tris, 30% glycerol, 10% SDS, 0.6 M DTT, 
0.012% bromophenol blue) and heating for 5 min at 95ºC. Equal amounts of protein 
were loaded into the gel and proteins were separated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE), using 4%-8% gels. Then, proteins 
were transferred electrophoretically to PVDF membranes (Millipore, Billerica, 
Massachusetts, USA). The membranes were blocked for 1 h at room temperature, in 
Tris-buffered saline (137 mM NaCl, 20 mM Tris-HCl, pH 7.6) containing 0.1% Tween-
20 (TBS-T) and 5% low-fat milk. The membranes were incubated with the primary 
antibody VGluT-1 1:10,000 and VGluT-2 1:5,000 (Sigma Aldrich, St.Louis, MO, USA); 
VGAT (1:2,000 from Synaptic Systems, Goettingen, Germany) and α1A P/Q Type 
calcium channel (1:200 from Alomone Labs, Jerusalem, Israel) overnight at 4ºC. After 
washing for 1 h in TBS-T with 0.5% low-fat milk, the membranes were incubated for 1 h 
at room temperature with the respective alkaline phosphatase-linked secondary 
antibody (1:20,000; GE Healthcare, Buckinghamshire, UK), prepared in TBS-T with 1% 
low-fat milk. The membranes were processed for protein detection using the Enhanced 
Chemi-Fluorescence system (ECF; GE Healthcare, Buckinghamshire, UK) and a Storm 
device (Molecular Dynamics, GE Healthcare, Buckinghamshire, UK). Digital 
quantification of bands intensity was performed using ImageQuant 5.0 software 
(Molecular Dynamics, Inc., Sunnyvale. CA, USA). The membranes were then reprobed 
and tested for β-actin (1:20,000; Sigma, St.Louis, MO, USA) immunoreactivity to prove 
that similar amounts of protein were applied in the gels. 
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4.10 Radioactivity assay and calculations 
The radioactivity released from the synaptosomal preparations was measured with a 
Packard 2900 Tricarb (Canberra, Australia) liquid scintillation spectrometer, equipped 
with Dynamic Color Corrected DPM Option providing absolute activity (disintegrations 
per minute, DPM) calculation and correction for different color quenching. The release 
of the transmitters was calculated as the percentage of the amount of radioactivity in 
the tissue at the sample collection time point. We expressed the radioactivity value 
from each sample (perfusate) as the % of the filter content at the period of time 
corresponding to the release of each sample, which is called as fractional release 
(FR%). 
 
4.11 Statistical Analysis 
Results are presented as mean ± SEM. Statistical comparisons between diabetic 
animals and respective age-matched controls were performed using the unpaired 
Student’s t-test. Differences were considered significant for p<0.05.  
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Legends 
Figure 1: Diabetes does not affect the protein content of vesicular glutamate 
transporters in the hippocampus. The protein levels of VGluT-1 and VGluT-2 were 
analyzed by immunoblotting in extracts of hippocampal synaptosomes (A and B) and in 
hippocampal total extracts (C and D) isolated from control and STZ-induced diabetic 
animals. Representative Western blots are presented above the graphs, with the 
respective loading controls (β-actin), to confirm that identical amounts of protein from 
control and diabetic samples were loaded into the gel. The results are expressed as 
percentage of age-matched controls, and data are presented as the mean ± SEM of at 
least 5 animals. 
 
Figure 2: Diabetes induces changes in the protein content of vesicular glutamate 
transporters in the retina. The protein levels of VGluT-1 and VGluT-2 were analyzed 
by immunoblotting in extracts of retinal synaptosomes (A and B) and in retinal total 
extracts (C and D) isolated from control and STZ-induced diabetic animals. 
Representative Western blots are presented above the graphs, with the respective 
loading controls (β-actin), to confirm that identical amounts of protein from control and 
diabetic samples were loaded into the gel. The results are expressed as percentage of 
age-matched controls, and data are presented as the mean ± SEM of at least 5 
animals. * p < 0.05, compared to age-matched control animals. 
 
Figure 3: Diabetes induces changes in the protein content of vesicular GABA 
transporter in hippocampal and retinal synaptosomes. The protein levels of VGAT 
were analyzed by immunoblotting in hippocampal (A) and retinal (B) synaptosomes, 
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and also in hippocampal (C) and retinal (D) total extracts, from diabetic animals and 
aged-matched controls. Representative western blots are presented above the graphs, 
with the respective loading controls (β-actin), to confirm that identical amounts of 
protein from control and diabetic samples were loaded in the gel. The results are 
expressed as percentage of age-matched controls, and data are presented as the 
mean ± SEM of at least 4 animals. * p < 0.05, *** p < 0.001, compared to age-matched 
control animals. 
 
Figure 4: The content of α1A subunit of P/Q type calcium channels decreases at 
two weeks of diabetes in hippocampal and retinal synaptosomes. The protein 
levels of α1A P/Q type calcium channels were analyzed by immunoblotting in 
hippocampal (A) and retinal (B) synaptosomes, and also in hippocampal (C) and retinal 
(D) total extracts, from diabetic animals and aged-matched controls. Representative 
western blots are presented above the graphs, with the respective loading controls (β-
actin), to confirm that identical amounts of protein from control and diabetic samples 
were loaded in the gel. The results are expressed as percentage of age-matched 
controls, and data are presented as the mean ± SEM of at least 4 animals. * p < 0.05, 
** p < 0.01, compared to age-matched control animals. 
 
Figure 5: Diabetes increases the basal release of glutamate after eight weeks of 
diabetes. Synaptosomes were simultaneously loaded with [14C]glutamate (besides 
[3H]GABA), and after 15 min of washout, 2 min perfusate samples were collected and 
radioactivity counted. Results are expressed as fractional release % (FR%). 
Synaptosomes were stimulated twice (S1 and S2) with 20 mM KCl for 30 sec each. (A) 
Glutamate release at two weeks of diabetes; (B) Glutamate release at eight weeks of 
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diabetes; (C-D) S1 and S2 at two and eight weeks time points for diabetic and age-
matched control animals; (E) S2/S1 ratio at two and eight weeks time points for 
diabetic and age-matched control animals. All data points represent the mean ± SEM 
of at least 8 animals; * p < 0.05, compared to age-matched control animals. 
 
Figure 6: Diabetes does not affect GABA release from hippocampal 
synaptosomes. Results were obtained from the same experiments shown in Figure 5. 
Synaptosomes were simultaneously loaded with [3H]GABA (besides [14C]glutamate), 
and after 15 min of washout, 2 min perfusate samples were collected and radioactivity 
counted. Results are expressed as fractional release % (FR%). Synaptosomes were 
stimulated twice (S1 and S2) with 20 mM KCl for 30 sec each. (A) GABA release at two 
weeks of diabetes; (B) GABA release at eight weeks of diabetes; (C-D) S1 and S2 at 
two and eight weeks time points for diabetic and age-matched control animals; (E) 
S2/S1 ratio at two and eight weeks time points for diabetic and age-matched control 
animals. All data points represent the mean ± SEM of at least 8 animals. 
 
Figure 7: Diabetes affects the release of GABA in retinal synaptosomes. 
Synaptosomes were loaded with [3H]GABA, and after 15 min of washout, 2 min 
perfusate samples were collected and radioactivity counted. Results are expressed as 
fractional release % (FR%). Synaptosomes were stimulated twice (S1 and S2) with 30 
mM KCl for 1 min each. (A) GABA release at two weeks of diabetes; (B) GABA release 
at eight weeks of diabetes; (C-D) S1 and S2 at two and eight weeks time points for 
diabetic and age-matched control animals; (E) S2/S1 ratio at two and eight weeks time 
points for diabetic and age-matched control animals. All data points represent the 
mean ± SEM of 11 animals. * p < 0.05 compared to age-matched control animals. 
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Table 1: Average weight and blood glucose levels of diabetic and aged-matched control rats. 
Diabetes duration Weight (g) Blood Glucose (mg/dL)
Control (n=15) 312.3±13.6 97.0±6.6
Diabetic (n=15) 240.1±8.2*** 467.8±26.9***
Control (n=15) 401.1±8.1 94.1±2.7
Diabetic (n=15) 278.5±7.9*** 431.0±19.9***
2 Weeks
8 Weeks
 
Measurements were made immediately before the sacrifice of the animals. ***p <0.001 
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